Assessment of the feasibility of using circulating tumor cells and peripheral blood cells as biomarkers for predicting the efficacy of concurrent chemoradiotherapy and durvalumab consolidation therapy in patients with locally advanced Non-small cell lung cancer
Latest Information Update: 18 May 2022
At a glance
- Drugs Antineoplastics (Primary) ; Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
Most Recent Events
- 18 May 2022 New trial record
- 13 Apr 2022 Results presented at the 113th Annual Meeting of the American Association for Cancer Research